JBC Ideal method for primary cell transfection

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, S.
Right arrow Articles by Hsieh, T.-s.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, S.
Right arrow Articles by Hsieh, T.-s.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 273, Issue 31, 19822-19828, July 31, 1998

Analysis of a Core Domain in Drosophila DNA Topoisomerase II
TARGETING OF AN ANTITUMOR AGENT ICRF-159

Steve Chang, Tao Hu, and Tao-shih Hsieh

From the Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710

To investigate the biochemical properties of individual domains of eukaryotic topoisomerase (topo) II, two truncation mutants of Drosophila topo II were generated, ND406 and core domain. Both mutants lack the ATPase domain, corresponding to the N-terminal 406 amino acid residues in Drosophila protein. The core domain also lacks 240 amino acid residues of the hydrophilic C-terminal region. The mutant proteins have lost DNA strand passage activity while retaining the ability to cleave the DNA and the sequence preference in protein/DNA interaction. The cleavage experiments carried out in the presence of several topo II poisons suggest that the core domain is the key target for these drugs. We have used glass-fiber filter binding assay and CsCl density gradient ultracentrifugation to monitor the formation of a salt-stable, protein-clamp complex. Both truncation mutant proteins can form a clamp complex in the presence of an antitumor agent, ICRF-159, suggesting that the drug targets the core domain of the enzyme and promotes the intradimeric closure at the N-terminal interface of the core domain. Furthermore, the salt stability of the closed protein clamp induced by ICRF-159 depends on the presence and closure of the N-terminal ATPase domain.

Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
Y. L. Lyu, J. E. Kerrigan, C.-P. Lin, A. M. Azarova, Y.-C. Tsai, Y. Ban, and L. F. Liu
Topoisomerase II{beta} Mediated DNA Double-Strand Breaks: Implications in Doxorubicin Cardiotoxicity and Prevention by Dexrazoxane
Cancer Res., September 15, 2007; 67(18): 8839 - 8846.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
T. Sengupta, M. Mukherjee, R. Das, A. Das, and H. K. Majumder
Characterization of the DNA-binding domain and identification of the active site residue in the 'Gyr A' half of Leishmania donovani topoisomerase II
Nucleic Acids Res., April 28, 2005; 33(8): 2364 - 2373.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Vaughn, S. Huang, I. Wessel, T. K. Sorensen, T. Hsieh, L. H. Jensen, P. B. Jensen, M. Sehested, and J. L. Nitiss
Stability of the Topoisomerase II Closed Clamp Conformation May Influence DNA-stimulated ATP Hydrolysis
J. Biol. Chem., March 25, 2005; 280(12): 11920 - 11929.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. V. Walker, K. C. Nitiss, L. H. Jensen, C. Mayne, T. Hu, P. B. Jensen, M. Sehested, T. Hsieh, and J. L. Nitiss
A Mutation in Human Topoisomerase II {alpha} Whose Expression Is Lethal in DNA Repair-deficient Yeast Cells
J. Biol. Chem., June 18, 2004; 279(25): 25947 - 25954.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
N. Vilain, M. Tsai-Pflugfelder, A. Benoit, S. M. Gasser, and D. Leroy
Modulation of drug sensitivity in yeast cells by the ATP-binding domain of human DNA topoisomerase II{alpha}
Nucleic Acids Res., October 1, 2003; 31(19): 5714 - 5722.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Classen, S. Olland, and J. M. Berger
Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187
PNAS, September 16, 2003; 100(19): 10629 - 10634.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. Renodon-Corniere, T. K. Sorensen, P. B. Jensen, J. L. Nitiss, B. Sokilde, M. Sehested, and L. H. Jensen
Probing the Role of Linker Substituents in Bisdioxopiperazine Analogs for Activity against Wild-Type and Mutant Human Topoisomerase IIalpha
Mol. Pharmacol., May 1, 2003; 63(5): 1159 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Skouboe, L. Bjergbaek, V. H. Oestergaard, M. K. Larsen, B. R. Knudsen, and A. H. Andersen
A Human Topoisomerase IIalpha Heterodimer with Only One ATP Binding Site Can Go through Successive Catalytic Cycles
J. Biol. Chem., February 14, 2003; 278(8): 5768 - 5774.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. Hu, H. Sage, and T.-s. Hsieh
ATPase Domain of Eukaryotic DNA Topoisomerase II. INHIBITION OF ATPase ACTIVITY BY THE ANTI-CANCER DRUG BISDIOXOPIPERAZINE AND ATP/ADP-INDUCED DIMERIZATION
J. Biol. Chem., February 15, 2002; 277(8): 5944 - 5951.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Patel, E. Jazrawi, A. M. Creighton, C. A. Austin, and L. M. Fisher
Probing the Interaction of the Cytotoxic Bisdioxopiperazine ICRF-193 with the Closed Enzyme Clamp of Human Topoisomerase IIalpha
Mol. Pharmacol., September 1, 2000; 58(3): 560 - 568.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
L. Bjergbaek, P. Kingma, I. S. Nielsen, Y. Wang, O. Westergaard, N. Osheroff, and A. H. Andersen
Communication between the ATPase and Cleavage/Religation Domains of Human Topoisomerase IIalpha
J. Biol. Chem., April 21, 2000; 275(17): 13041 - 13048.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. K. Morris, C. L. Baird, and J. E. Lindsley
Steady-state and Rapid Kinetic Analysis of Topoisomerase II Trapped as the Closed-clamp Intermediate by ICRF-193
J. Biol. Chem., January 28, 2000; 275(4): 2613 - 2618.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. H. Jensen, K. C. Nitiss, A. Rose, J. Dong, J. Zhou, T. Hu, N. Osheroff, P. B. Jensen, M. Sehested, and J. L. Nitiss
A Novel Mechanism of Cell Killing by Anti-topoisomerase II Bisdioxopiperazines
J. Biol. Chem., January 21, 2000; 275(3): 2137 - 2146.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Olland and J. C. Wang
Catalysis of ATP Hydrolysis by Two NH2-terminal Fragments of Yeast DNA Topoisomerase II
J. Biol. Chem., July 30, 1999; 274(31): 21688 - 21694.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Wessel, L. H. Jensen, P. B. Jensen, J. Falck, A. Rose, M. Roerth, J. L. Nitiss, and M. Sehested
Human Small Cell Lung Cancer NYH Cells Selected for Resistance to the Bisdioxopiperazine Topoisomerase II Catalytic Inhibitor ICRF-187 Demonstrate a Functional R162Q Mutation in the Walker A Consensus ATP Binding Domain of the {{alpha}} Isoform
Cancer Res., July 1, 1999; 59(14): 3442 - 3450.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 1998 by the American Society for Biochemistry and Molecular Biology.